Global Rituximab Biosimilars Market

Key Insights On The Rituximab Biosimilars Market 2024 – Size, Driver, And Major Players

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Rituximab Biosimilars Global Market Report 2024, the rituximab biosimilars market is expected to show significant growth in the forecast period.

The rituximab biosimilars market has seen significant expansion in recent years, driven by various factors such as government initiatives, increased healthcare expenditure, and advancements in biopharmaceutical research. This blog delves into the key drivers, trends, and future projections for this rapidly growing market.

Market Growth Overview

Historic Growth (2023-2024)

  • Market Size Increase: From $2.66 billion in 2023 to $3.02 billion in 2024
  • CAGR: 13.3%
  • Key Drivers:
    • Government initiatives
    • Increased healthcare expenditure
    • Enhanced biopharmaceutical R&D
    • Cost-effectiveness of biosimilars
    • Growth in emerging markets

Forecasted Growth (2024-2028)

  • Projected Market Size: $4.89 billion by 2028
  • CAGR: 12.8%
  • Key Drivers:
    • Aging population
    • Improved healthcare access
    • Rising prevalence of chronic diseases

View More On The Rituximab Biosimilars Market Report 2024 –

Key Trends in the Rituximab Biosimilars Market

Revised FDA Regulations

  • Impact: Facilitates biosimilar drug development
  • Outcome: Easier market entry for new biosimilars

Strategic Partnerships and Collaborations

  • Purpose: To expand R&D activities and enhance drug development
  • Examples: Alliances between major pharmaceutical companies and biotech firms

Extensive R&D Investment

  • Focus: Development of effective and innovative biosimilars
  • Result: Higher quality and more diverse treatment options

Rising Non-Hodgkin’s Lymphoma Cases

Contribution to Market Growth

  • NHL Prevalence: Major driver for rituximab biosimilars demand
  • Statistics: NHL is the most common cancer in the USA, with approximately 81,560 new cases expected in 2021
  • Impact: Increased diagnosis leads to higher demand for effective treatments

Major Market Players

  • Companies: Teva/Cellitron, Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Sandoz, and others
  • Focus: FDA-approved biosimilars for competitive advantage

FDA-Approved Rituximab Biosimilars

Competitive Edge

  • Notable Approval: Amgen’s RIABNI (rituximab-arrx) in June 2022
  • Uses: Approved for multiple indications, including Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and rheumatoid arthritis (RA)

Market Segmentation

By Route of Administration

  • Categories: Subcutaneous, Intravenous, Molecular Type

By Application

  • Uses: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications

By Distribution Channel

  • Channels: Hospital Pharmacy, Retail Pharmacy, Mail Order

Regional Insights

Largest Market in 2023

  • Region: North America

Fastest-Growing Region

  • Region: Middle East (forecast period)


The rituximab biosimilars market is on a robust growth trajectory, bolstered by increased healthcare expenditure, strategic industry collaborations, and a rising prevalence of chronic diseases. With significant investments in R&D and favorable regulatory environments, the market is set to expand rapidly, providing more affordable and effective treatment options for patients worldwide.

Request A Sample Of The Global Rituximab Biosimilars Market Report 2024: